The compound, which is of unknown structure, appears to be more tolerable than previous attempts of small molecule development against related G protein-coupled receptor (GPCR) targets such as glucagon, which despite clear benefits on diabetes in clinical trials (Cheng et al. 2020) were ultimately shelved due to hepatic impairment (Lafferty et al. 2022). The gene discussed is GCG; the disease is diabetes mellitus.